• Skip to primary navigation
  • Skip to main content
  • Skip to footer

HepVu

HepVu

An estimated 3.5 million people in the U.S. are living with chronic Hepatitis C infection.

  • View the Map
  • Local Data
  • Find Services
  • News & Updates
  • Events
  • Tools & Resources
Home News & Updates 2021: A Year in Review

2021: A Year in Review

December 21, 2021

As we come to the end of 2021, HepVu takes a step back and looks at this year’s highlights – from new data to insightful infographics and Q&As with viral hepatitis and opioid experts.

County-level Hepatitis C-Related Mortality Data:

HepVu released new interactive maps visualizing U.S. county-level Hepatitis C-related mortality, illustrating how factors such as age and geographic region affect health outcomes. Published in Hepatology, the data demonstrate that Hepatitis C-related mortality has been decreasing across the U.S. since 2013.

Key findings included:

  • Between 2013 and 2017, 1 in 5 counties saw an increase in Hepatitis C-related death rates, despite Hepatitis C-related mortality decreasing nationally.
  • In 2017, the West, Southwest, Appalachia, and northern Florida saw the highest rates of Hepatitis C-related mortality.
  • The highest burden of Hepatitis C-related death rates among people under 40 in 2017 occurred in New Mexico, Oklahoma, and Appalachia. The rates in the central Appalachian region continued to increase through 2017. These regions are also experiencing increases of injection drug use as a result of the ongoing opioid epidemic.

Opioid Prescription and Mortality Rates:

HepVu added county-level opioid prescription and overdose mortality rates data and maps to visualize the relationship between opioid prescription practices and drug overdose mortality and illustrate how the differences among geographic regions can affect health outcomes. These maps visualize 2019 county-level opioid prescription and overdose mortality rates from 2014 to 2019 across the U.S.

Treatment Restrictions:

HepVu added new data and comparison maps visualizing Hepatitis C treatment restrictions at the state-level from 2017 to 2021, utilizing insights from the Center for Health Law and Policy Innovation (CHLPI) at Harvard Law School and the National Viral Hepatitis Roundtable (NVHR)’s Hepatitis C: The State of Medicaid Access report. HepVu also enhanced its state profiles to feature each state’s Hepatitis C treatment restrictions.

The U.S. has made tremendous progress in eliminating or scaling back these treatment restrictions since tracking began in 2017. Due to the continued and diligent work of viral hepatitis organizations such as CHLPI and NVHR many states have eliminated or loosened restrictions.

Our most shared infographics

Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn

A few of our most read blogs this year

July 28, 2021

U.S. Congresswoman Grace Meng on Funding Viral Hepatitis Surveillance and the Congressional Hepatitis Caucus

Read More

July 28, 2021

Jim Macrae on Health Disparities in Viral Hepatitis Elimination

Read More

January 7, 2021

Dr. Carolyn Wester on CDC’s Division of Viral Hepatitis 2025 Strategic Plan

Read More

May 19, 2021

Patient Perspective on the Challenges of Treatment Restrictions in Hepatitis C Care

Read More

Most Read

Hepatitis C Treatment Restrictions
Combatting Hepatitis C Among People Who Use Drugs in Appalachia
What’s New in Viral Hepatitis – February
Share Facebook Twitter LinkedIn Email

Keep Reading

February 2, 2023

HepVu Welcomes New HepVu Technical Advisory Group

Read More

February 2, 2023

What's New in Viral Hepatitis - February 2023

Read More

December 14, 2022

2022: A Year in Review

Read More

December 12, 2022

HepVu Adds 2020 County-Level Opioid Maps and Data

Read More

Sign up for HepVu updates.

Footer

AIDSVu HepVu

HepVu is presented by Emory University’s Rollins School of Public Health in partnership with Gilead Sciences, Inc.

  • About
  • FAQ
  • Data Methods
  • Datasets

Questions?
Info@HepVu.org

Media Inquiries
(202) 854-0480
Media@HepVu.org

Follow Us

  • Facebook
  • Twitter

© 2023 HepVu. All Rights Reserved.

  • Privacy Policy
  • Contact Us

Get HepVu in Your Inbox

Sign up to stay informed on new data, maps, expert Q&As, and infographics about Hepatitis C and opioids where you live.